Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ETS2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ETS2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ETS2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ETS2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ETS2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ETS2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ETS2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ETS2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ETS2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ETS2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
GO:0001704 | Cervix | CC | formation of primary germ layer | 27/2311 | 121/18723 | 1.49e-03 | 1.16e-02 | 27 |
GO:0007369 | Colorectum | AD | gastrulation | 53/3918 | 185/18723 | 7.60e-03 | 4.60e-02 | 53 |
GO:00073691 | Colorectum | SER | gastrulation | 43/2897 | 185/18723 | 3.44e-03 | 2.92e-02 | 43 |
GO:00073692 | Colorectum | FAP | gastrulation | 42/2622 | 185/18723 | 8.97e-04 | 9.10e-03 | 42 |
GO:0009952 | Colorectum | FAP | anterior/posterior pattern specification | 41/2622 | 201/18723 | 7.82e-03 | 4.63e-02 | 41 |
GO:00073693 | Colorectum | CRC | gastrulation | 36/2078 | 185/18723 | 5.54e-04 | 7.70e-03 | 36 |
GO:00099521 | Colorectum | CRC | anterior/posterior pattern specification | 36/2078 | 201/18723 | 2.56e-03 | 2.40e-02 | 36 |
GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
GO:00017044 | Esophagus | ESCC | formation of primary germ layer | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
GO:00073697 | Oral cavity | OSCC | gastrulation | 95/7305 | 185/18723 | 4.17e-04 | 2.54e-03 | 95 |
GO:00017043 | Oral cavity | OSCC | formation of primary germ layer | 65/7305 | 121/18723 | 7.08e-04 | 3.90e-03 | 65 |
GO:000736913 | Oral cavity | EOLP | gastrulation | 39/2218 | 185/18723 | 2.29e-04 | 2.25e-03 | 39 |
GO:000170412 | Oral cavity | EOLP | formation of primary germ layer | 24/2218 | 121/18723 | 7.53e-03 | 3.62e-02 | 24 |
GO:00073696 | Prostate | BPH | gastrulation | 50/3107 | 185/18723 | 2.20e-04 | 1.78e-03 | 50 |
GO:00017042 | Prostate | BPH | formation of primary germ layer | 35/3107 | 121/18723 | 4.80e-04 | 3.42e-03 | 35 |
GO:000736912 | Prostate | Tumor | gastrulation | 52/3246 | 185/18723 | 1.76e-04 | 1.55e-03 | 52 |
GO:000170411 | Prostate | Tumor | formation of primary germ layer | 36/3246 | 121/18723 | 5.22e-04 | 3.82e-03 | 36 |
GO:00073699 | Skin | AK | gastrulation | 41/1910 | 185/18723 | 1.32e-06 | 4.13e-05 | 41 |
GO:00017045 | Skin | AK | formation of primary germ layer | 30/1910 | 121/18723 | 3.12e-06 | 8.17e-05 | 30 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05166210 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
hsa0516638 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
hsa0516644 | Oral cavity | EOLP | Human T-cell leukemia virus 1 infection | 64/1218 | 222/8465 | 1.37e-08 | 1.83e-07 | 1.08e-07 | 64 |
hsa0516654 | Oral cavity | EOLP | Human T-cell leukemia virus 1 infection | 64/1218 | 222/8465 | 1.37e-08 | 1.83e-07 | 1.08e-07 | 64 |
hsa0516628 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa05166112 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa0516629 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
hsa0516637 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
hsa0516612 | Stomach | GC | Human T-cell leukemia virus 1 infection | 41/708 | 222/8465 | 9.06e-07 | 1.71e-05 | 1.20e-05 | 41 |
hsa0516613 | Stomach | GC | Human T-cell leukemia virus 1 infection | 41/708 | 222/8465 | 9.06e-07 | 1.71e-05 | 1.20e-05 | 41 |
hsa0516621 | Stomach | CAG with IM | Human T-cell leukemia virus 1 infection | 38/640 | 222/8465 | 1.33e-06 | 2.12e-05 | 1.49e-05 | 38 |
hsa0516631 | Stomach | CAG with IM | Human T-cell leukemia virus 1 infection | 38/640 | 222/8465 | 1.33e-06 | 2.12e-05 | 1.49e-05 | 38 |
hsa051664 | Stomach | CSG | Human T-cell leukemia virus 1 infection | 39/633 | 222/8465 | 3.66e-07 | 6.43e-06 | 4.62e-06 | 39 |
hsa051665 | Stomach | CSG | Human T-cell leukemia virus 1 infection | 39/633 | 222/8465 | 3.66e-07 | 6.43e-06 | 4.62e-06 | 39 |
hsa051666 | Stomach | CAG | Human T-cell leukemia virus 1 infection | 24/368 | 222/8465 | 3.28e-05 | 3.95e-04 | 3.16e-04 | 24 |
hsa051667 | Stomach | CAG | Human T-cell leukemia virus 1 infection | 24/368 | 222/8465 | 3.28e-05 | 3.95e-04 | 3.16e-04 | 24 |
hsa0516610 | Stomach | SIM | Human T-cell leukemia virus 1 infection | 28/465 | 222/8465 | 3.02e-05 | 3.82e-04 | 3.07e-04 | 28 |
hsa0516611 | Stomach | SIM | Human T-cell leukemia virus 1 infection | 28/465 | 222/8465 | 3.02e-05 | 3.82e-04 | 3.07e-04 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ETS2 | SNV | Missense_Mutation | | c.1236N>C | p.Met412Ile | p.M412I | P15036 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ETS2 | SNV | Missense_Mutation | | c.557N>G | p.Ser186Cys | p.S186C | P15036 | protein_coding | tolerated(0.11) | benign(0.425) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
ETS2 | SNV | Missense_Mutation | | c.443N>C | p.Leu148Pro | p.L148P | P15036 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
ETS2 | SNV | Missense_Mutation | rs777149491 | c.829N>A | p.Asp277Asn | p.D277N | P15036 | protein_coding | tolerated(0.11) | possibly_damaging(0.632) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ETS2 | SNV | Missense_Mutation | | c.554N>T | p.Thr185Ile | p.T185I | P15036 | protein_coding | tolerated(0.12) | benign(0.121) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD |
ETS2 | insertion | Frame_Shift_Ins | novel | c.712_713insGTCAGAGAGCTTCCTTCCCTCTCCAGAAAATAAATTATTC | p.Met238SerfsTer56 | p.M238Sfs*56 | P15036 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ETS2 | SNV | Missense_Mutation | rs372145357 | c.559N>A | p.Val187Ile | p.V187I | P15036 | protein_coding | tolerated(0.55) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ETS2 | SNV | Missense_Mutation | | c.127N>G | p.Leu43Val | p.L43V | P15036 | protein_coding | tolerated(0.2) | benign(0.251) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ETS2 | SNV | Missense_Mutation | | c.431N>C | p.Lys144Thr | p.K144T | P15036 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ETS2 | SNV | Missense_Mutation | | c.825N>A | p.Asp275Glu | p.D275E | P15036 | protein_coding | tolerated(0.79) | benign(0) | TCGA-AA-A02O-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |